Related Experiment Video
Updated: Jun 21, 2025
08:01
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
7.3K
PANoptosis: a novel target for cardiovascular diseases
Qi Xiang1, Zhen-Xi Geng1, Xin Yi2
1Division of Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Trends in Pharmacological Sciences
|July 13, 2024
Summary
PANoptosis, an inflammatory cell death pathway, is a potential therapeutic target. This review explores its role in cardiovascular diseases and therapeutic strategies, offering a new approach to treatment.
Area of Science:
- Immunology
- Cell Biology
- Cardiovascular Medicine
Background:
- PANoptosis is a distinct inflammatory lytic cell death pathway.
- It is initiated by innate immune sensors and involves caspases and RIPKs.
- Its role in cardiovascular diseases remains under-explored compared to cancer and inflammatory conditions.
Purpose of the Study:
- To review the evidence of PANoptosis in various cardiovascular diseases.
- To explore therapeutic agents targeting PANoptosis for cardiovascular conditions.
- To propose PANoptosis as a novel therapeutic target for cardiovascular diseases.
Main Methods:
- Literature review of studies on PANoptosis and cardiovascular diseases.
- Analysis of existing therapeutic strategies targeting PANoptosis.
- Synthesis of evidence linking PANoptosis to cardiomyopathy, atherosclerosis, myocardial infarction, myocarditis, and aortic aneurysm/dissection.
Main Results:
- PANoptosis plays a role in several cardiovascular diseases, including cardiomyopathy, atherosclerosis, myocardial infarction, myocarditis, and aortic aneurysm/dissection.
- Targeting PANoptosome components offers a strategy to inhibit this cell death pathway.
- Existing research has predominantly focused on cancer and infectious/inflammatory diseases, with limited attention to cardiovascular implications.
Conclusions:
- PANoptosis is a significant factor in cardiovascular diseases.
- Targeting PANoptosis presents a novel therapeutic avenue for cardiovascular conditions.
- Further research into PANoptosis in cardiovascular diseases is warranted to develop effective treatments.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419